CALL FOR APPLICATIONS! 2018-2019 Petrie-Flom Center Student Fellowship

Petrie-Flom Center, Harvard Law School, August 10, 2018

What do a MacArthur Genius award winner, several health law professors at top schools, executive directors of leading health law centers, an associate chief counsel of the FDA, and partners and associates at top health care law firms all have in common? The Petrie-Flom Center Student…

Read More

Update: UK Ministers Quit Over Brexit

BBC, July 9, 2018
Interview featuring Rachel Sachs (Academic Fellow Alumna)

From the interview: We consider the implications for Brexit as two senior UK ministers resign. David Henig is UK director of the European Centre For International Political Economy. He explains why this could be just the start of a government crisis. President…

Read More

HHS forced to choose migrants over medicines

Politico, July 18, 2018
By Dan Diamond, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: Echoing the pharma industry, Verma stressed that the state's request violated current law — the first time she's publicly cited a legal defense. “f you want to go forward with negotiating with…

Read More

What Pfizer, Trump, and consumers got out of a surprising deal — and what they didn’t

STAT, July 11, 2018
By Erin Mershon and Ike Swetlitz, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: After months of pledging he would get pharmaceutical companies to lower their prices, President Trump can now say that he pressed the CEO of a major drug maker, Pfizer, to back down on a series of price hikes.

Read More

The Health 202: ‘ACA’ removed from swaths of website, watchdog reports

Washington Post, July 12, 2018
By Colby Itkowitz, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: As The Post’s Damian Paletta also noted, the announcement was an example of Trump’s successful use of the presidential bully pulpit. “This is not an industry that compromises,” Rachel Sachs, an associate professor…

Read More

The News on Drug Prices? Nothing Good

The New York Times, July 17, 2018
By The Editorial Board, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: “It takes away a substantial tool that a lot of states were hoping to use,” says Rachel Sachs, a law professor and drug policy expert at Washington University in St. Louis. It also points to a hypocrisy, she says. “They’re…

Read More

Pro-ACA group: Court pick Kavanaugh refused to uphold pre-existing condition ban

PolitiFact, July 18, 2018
By Jon Greenberg, quoting Allison K. Hoffman (Academic Fellow Alumna)

From the article: For the makers of the ad, this is very simple. "Two judges upheld the Affordable Care Act and its patient protections, and he declined to uphold it," Demand Justice executive director Brian Fallon said. "He could…

Read More

Donald Trump’s phony war on high prescription drug prices, explained

Vox, July 13, 2018
By Dylan Scott, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: Pfizer ended up agreeing to postpone its price hikes for now. The president was happy to take credit for that news, even if all he had really won was a temporary delay. Certainly not a “massive” cut. “It’s…

Read More

Fox News pundit says Brett Kavanaugh is pro-Obamacare. Is he?

PolitiFact, July 11, 2018
By Jon Greenberg, quoting Allison K. Hoffman (Academic Fellow Alumna)

From the article: In the 2011 case, Blumstein said Kavanaugh showed "a traditional norm of judicial restraint." Mark Hall at Wake Forest University echoed that point. He sees Kavanaugh’s opinions as focused on legal fundamentals. …

Read More

As Arkansas ushers in new Trump-era Medicaid rules, thousands fear losing benefits

Reuters, July 10, 2018
By Yasmeen Abutaleb, quoting Allison K. Hoffman (Academic Fellow Alumna)

From the article: Days after the ruling, Kentucky Governor Matt Bevin cut dental and vision benefits for some 460,000 state Medicaid recipients, saying the benefits were dependent on implementation of the community engagement requirements. Without the new rules, “immediate…

Read More

Abortion row reignites as US Supreme Court justice retires

The Citizen, June 29, 2018
By AFP, quoting Allison K. Hoffman (Academic Fellow Alumna)

From the article: Allison Hoffman, a law professor at the University of Pennsylvania, says many Supreme Court decisions that fell short of a full repeal of Row vs Wade have nevertheless eroded women’s rights. “If repealed,…

Read More

Understanding the Development Challenges Associated with Emerging Non-Traditional Antibiotics

Duke-Margolis Center for Heath Policy, June 14, 2018
Webcast featuring Jonathan J. Darrow (Student Fellow Alumnus)

From the webcast: Convened by the Duke-Robert J. Margolis, MD, Center for Health Policy at Duke University and supported by a cooperative agreement with FDA, this public event will focus on the range of non-traditional pharmaceutical approaches being developed to…

Read More

CMS quit test of pricey cancer treatment amid concerns over industry role

Politico, July 9, 2018
By Sarah Karlin-Smith and David Pittman, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: “Coming from an administration which has a stated goal of trying to reduce drug pricing, trying to reduce overall drug spending and health care spending … at every turn this administration has taken steps in the opposite direction and…

Read More

Viagra goes up AGAIN: Pfizer hikes the cost of 100 best-sellers a month after Trump said he'd persuaded Big Pharma to carry out 'massive' price drops

Daily Mail, July 2, 2018
By Mia De Graaf, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: Economists are now calling on the Department of Health and Human Services to clarify what kind of measures they were planning on levying against companies that did not stick to the plan.  'July 1 is a very…

Read More

Tempering Expectations of Breakthrough Therapy Designated Drugs

Journal of Clinical Pathways, June 10, 2018
Interviewing Jonathan J. Darrow (Student Fellow Alumnus)

From the interview: A recent study published in the Journal of Clinical Oncology (online June 20, 2018; doi:10.1200/JCO/2017.77.1592) sought to evaluate the United States Food and Drug Administration (FDA) breakthrough therapy designation…

Read More

Precision Medicines Approved More Quickly, With Less Data

MedPage Today, May 25, 2018
Shannon Firth, quoting Jonathan J. Darrow (Student Fellow Alumnus)

From the article: Pivotal trials for precision medicines were scarcer, less likely to be controlled or blinded, and had fewer participants than those for other agents, the study found.  The less rigorous design makes it more…

Read More

JAMA Forum: The Risks and Benefits of Expedited Drug Reviews

JAMA Forum, May 23, 2018
Austin Frakt, citing paper co-authored by Jonathan J. Darrow (Student Fellow Alumnus)

From the article: The US Food and Drug Administration (FDA) oversees several programs that expedite approval of certain drugs that treat serious conditions and address unmet medical needs. On average, a drug in an expedited program reaches market almost a year sooner…

Read More

Trump unveils plan to cut drug prices

The Lancet, June 2, 2018, vol. 391, no. 10136
Susan Jaffe, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: A trade association that represents PBMs disagrees. Eliminating rebates would leave patients and insurers “at the mercy of drug manufacturer pricing strategies”, according to a statement from the Pharmaceutical Care Management Association.…

Read More

Is Trump giving the EU higher drug prices too?

DW, June 1, 2018
Lindsey Rae Gjording, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: Through single-payer health care systems the EU is able to regulate consumer costs at reasonable levels. It also makes decisions about what new drugs are worth spending taxpayer money on and how to fairly value them. Without…

Read More

Trump Wants Medicaid to Push for Lower Drug Prices – But Will Patients Be Hurt?

PEW, May 30, 2018
Michael Ollove, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: While 74 percent of closed formularies result in lower prices, 21 percent result in price increases, a 2016 report in the American Journal of Managed Care found. And 29 percent of patients were affected by formulary exclusions. …

Read More